[Character | Li Zigang] Cooperate in many ways to tackle COVID-19

On February 2, Professor Li Zigang, senior researcher of Shenzhen Bay Laboratory and convener of Pingshan Biomedical R&D and Transformation Center, said in an interview with Shenzhen Business Daily that Shenzhen Bay Laboratory conducts research on the new coronavirus from many aspects such as diagnostic reagents, drug development, and therapeutic antibodies, and organizes a research team together with Shenzhen Third People's Hospital, Shenzhen CDC, Shenzhen China Resources Sanjiu, and Scripps Research to conduct research on the new coronavirus.

On February 2, Professor Li Zigang, senior researcher of Shenzhen Bay Laboratory and convener of Pingshan Biomedical R&D and Transformation Center, pointed out in an interview with reporters that when there are many phenomena that are inconsistent with common sense in the scientific research process of new crown pneumonia, it is better to let the bullet fly for a while, and when there are more details and more explanations, you will have a deeper understanding of it.

Shenzhen Bay Laboratory is the second batch of laboratories in Guangdong Province, mainly focusing on life information and biomedicine. According to reports, Shenzhen Bay Laboratory has been insisting on reporting the research progress of the new coronavirus (2019-nCoV), summarizing the research results of various institutions in the world on the new crown pneumonia, and providing reference for authorities at all levels to respond to the new crown pneumonia epidemic, and has released 16 issues of newsletters so far.

In addition, in this new crown pneumonia epidemic blocking battle, Shenzhen Bay Laboratory organized scientific research forces to conduct research on the new coronavirus from diagnostic reagents, drug development, therapeutic antibodies and other aspects, and organized a research team together with Shenzhen Third People's Hospital, Shenzhen CDC, Shenzhen China Resources Sanjiu, and Scripps Research to conduct research on the new coronavirus.

Li Zigang, who completed his postdoctoral research at Harvard University in 2010, focuses on the use of mild chemical methods to solve biological problems at the intersection of chemistry and biology. He believes that the current public should take a scientific attitude in the face of the new crown pneumonia epidemic, first of all, do not panic, because from the published papers and released cases, the case fatality rate of new crown pneumonia is about 2.7%, although the case fatality rate is stronger than ordinary influenza, but far lower than SARS coronavirus, Ebola virus or H7N9 influenza virus, so some people regard it as a relatively large flu.

He also stressed that in the face of many news about drug development on the Internet, everyone should be cautious while rejoicing. "Because drug research and development is a relatively long process, it is very likely that before the new crown pneumonia epidemic passes, the specific drugs that really target the new crown pneumonia, whether it is vaccines, antibodies, or small molecule chemical drugs, may not be able to really get practical, which everyone should be mentally prepared."

At present, the new crown pneumonia epidemic is a hot event of concern from all walks of life, and everyone, regardless of whether they have a scientific background or not, will track this matter and report great enthusiasm for scientific progress. In the process, scientists are also exposed to complex information and even contradictory things. Li Zigang believes that these phenomena should be viewed scientifically and rationally.

He pointed out that scientific research emphasizes bold assumptions and careful verification, and the research process is spiraling, and there are often some contradictory phenomena at first glance.

"But if you read the details carefully, you will see that they validate each other again." At this time, you can borrow the lines of a movie, if you are a non-professional, for a lot of things that do not conform to common sense and feel incomprehensible, you may wish to let the bullets fly for a while, wait until there are more details, more explanations, so that you may have a deeper understanding of the new crown pneumonia. ”

Education Experience:

2009.04-2010.06 Postdoctoral Fellow, National Cancer Center, Harvard University, Co-supervisor: Gregory Verdine2004.09-2008.12

Ph.D. in Chemistry, University of Chicago, Supervisor: Chuan He2001.09-2004.07

Tulane University, Master of Chemistry, Supervisor: Chao-Jun Li1996.09-2001.07

University of Science and Technology of China, Bachelor, Supervisor: Zhou Yifeng.

Awards:

2019  ACP Lectureship Award

2018 Second Prize of Entrepreneurial Achievement Award (Establishment and Promotion and Application of Individualized Tissue Engineering Regenerative Cartilage Transplantation Treatment System)

2018 Shenzhen Science and Technology Award Natural Science Award Second Prize (Stable Helical Peptide Method and Application Research)

2018 China Industry-University-Research Cooperation Innovation Award

2018 Shenzhen Outstanding Teacher

2017 Bayer Scholars

2017 Third Prize of Chinese Medical Science and Technology Award (Establishment and Promotion and Application of Tissue Engineering Cartilage Transplantation System)

2016 Guangdong Province Special Branch Plan <> million project leading talents

2013 Hubei Province Chutian Scholar Chair Professor

2013 Shenzhen Outstanding Youth

2012 Shenzhen Overseas High-level Talents

2011 Shenzhen high-level talent

2010 Peking University Hundred Talents Program

2009-2010 American Cancer Center Postdoctoral Fellow

2008-2009 Hubble Ph.D. Thesis Fellowship, University of Chicago

Written by | Read Tron/Shenzhen Business Daily reporter Wang Hairong

Edit |